Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T72039 |
CLK1-IN-3
|
DYRK; CDK; Autophagy | Autophagy; Cell Cycle/Checkpoint; Tyrosine Kinase/Adaptors |
CLK1-IN-3 是一种+具有选择性和高效的性 Clk1 抑制剂,其 IC50 为 5 nM,比对 Dyrk1A 的亲和力高300对倍。CLK1-IN-3 对 Clk2 和 Clk4 也显示出高效的抑制作用,IC50 值分别为 42 和 108 nM。CLK1-IN-3 在体外有效诱导自噬 (autophagy),可用于预防和人治疗急性肝损伤 (ALI)。 | |||
T23897 |
CLK1/2-IN-3
CLK1/2 inhibitor 3,CLK1/2-inhibitor-3,CLK1/2 IN 3,CLK1/2IN3 |
CDK | Cell Cycle/Checkpoint |
CLK1/2-IN-3(Cpd-3) 是一种具有高效性和选择性的 CLK1 和 CLK2 抑制剂,抗增殖活性,抑制 CLK1、CLK2、SRPK1、SRPK2、SRPK3 的 的活性。CLK1/2-IN-3 可诱导核斑点扩大,可诱导S6K pre-mRNA选择性剪接和随后抑制多种癌细胞类型细胞生长。 | |||
T36684 | Ipivivint | ||
Ipivivint, a first-in-class, orally active and potent CDC-like kinase (CLK) inhibitor, inhibits CLK1 (IC50=1.4 μM), CLK2 (IC50=0.002 μM) and CLK3 (IC50=0.022 μM). Ipivivint reduces Wnt pathway signaling gene expression through inhibiting CLK activity and serine and arginine rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity. Ipivivint can be used for the research of cancer[1]. Ipivivint (SW480 cells; 0.01~10 μM; 1 hour) potently inhibits SRSF5/6 phosphorylation[1].Ip... |